TRANSITION, SEPARATION AND RELEASE OF CLAIMS AGREEMENTTransition, Separation and Release of Claims Agreement • July 17th, 2019 • Merrimack Pharmaceuticals Inc • Pharmaceutical preparations • Massachusetts
This Transition, Separation and Release of Claims Agreement (the “Agreement”) is being provided to Daryl C. Drummond (“Executive”) on June 14, 2019 (the “Receipt Date”) and is made as of the Agreement Effective Date (as defined below) by and between Executive and Merrimack Pharmaceuticals, Inc. (the “Company”) (together, the “Parties”).
TRANSITION, SEPARATION AND RELEASE OF CLAIMS AGREEMENTTransition, Separation and Release of Claims Agreement • October 13th, 2017 • Ocular Therapeutix, Inc • Pharmaceutical preparations • Massachusetts
This Transition, Separation and Release of Claims Agreement (the “Agreement”) is made as of the Agreement Effective Date (as defined below) by and between Ocular Therapeutix, Inc. (the “Company”) and James Fortune (“Executive”) (together, the “Parties”).
TRANSITION, SEPARATION AND RELEASE OF CLAIMS AGREEMENTTransition, Separation and Release of Claims Agreement • June 10th, 2021 • National CineMedia, Inc. • Services-advertising • Colorado
This Transition, Separation and Release of Claims Agreement (the “Agreement”) is made as of the Agreement Effective Date (as defined in Section 5 below) by and between National CineMedia, Inc. (“NCM” or the “Company”) and Clifford E. Marks (“Mr. Marks”) (together, the “Parties”).
TRANSITION, SEPARATION AND RELEASE OF CLAIMS AGREEMENTTransition, Separation and Release of Claims Agreement • May 30th, 2019 • Ocular Therapeutix, Inc • Pharmaceutical preparations • Massachusetts
This Transition, Separation and Release of Claims Agreement (the “Agreement”) is made as of the Agreement Effective Date (as defined below) by and between Ocular Therapeutix, Inc. (the “Company”) and Dr. Amarpreet S. Sawhney (“Executive”) (together, the “Parties”).
TRANSITION, SEPARATION AND RELEASE OF CLAIMS AGREEMENTTransition, Separation and Release of Claims Agreement • March 2nd, 2022 • Schrodinger, Inc. • Pharmaceutical preparations • New York
This Transition, Separation and Release of Claims Agreement (the “Agreement”) is entered into by and between Schrödinger, Inc. (the “Company”) and Joel Lebowitz (“Executive”) (together, the “Parties”).
TRANSITION, SEPARATION AND RELEASE OF CLAIMS AGREEMENTTransition, Separation and Release of Claims Agreement • April 17th, 2017 • Endurance International Group Holdings, Inc. • Services-prepackaged software • Massachusetts
This Transition, Separation and Release of Claims Agreement (the “Agreement”) is made as of April 17, 2017 (the “Effective Date”) between Endurance International Group Holdings, Inc. (“Endurance” or the “Company”) and Hari Ravichandran (“Executive”) (together, the “Parties”).
TRANSITION, SEPARATION AND RELEASE OF CLAIMS AGREEMENTTransition, Separation and Release of Claims Agreement • December 19th, 2019 • National CineMedia, Inc. • Services-advertising • Colorado
This Transition, Separation and Release of Claims Agreement (the “Agreement”) is made as of the Agreement Effective Date (as defined in Section 7 below) by and between National CineMedia, Inc. (“NCM” or the “Company”) and Katherine L. Scherping (“Ms. Scherping”) (together, the “Parties”).
TRANSITION, SEPARATION AND RELEASE OF CLAIMS AGREEMENTTransition, Separation and Release of Claims Agreement • July 25th, 2018 • Nabriva Therapeutics PLC • Pharmaceutical preparations • Pennsylvania
This Transition, Separation and Release of Claims Agreement (the “Agreement”) is made as of the Agreement Effective Date (as defined below) between Nabriva Therapeutics US, Inc. (the “Company”) and Colin Broom (“Executive”) (together, the “Parties”). The Parties agree that this Agreement is contingent on the closing of the transaction (the “Closing”) contemplated by the Agreement and Plan of Merger dated as of July 23, 2018 (the “Purchase Agreement”) by and among Nabriva Therapeutics plc (the “Parent”), Zuperbug Merger Sub I, Inc., Zuperbug Merger Sub II, Inc., Zavante Therapeutics, Inc. and Cam Gallagher, solely in his capacity as the initial Stockholder Representative, and shall become effective as of the Closing. In the event the Closing does not occur, this Agreement shall have no further force and effect and shall be null and void.
TRANSITION, SEPARATION AND RELEASE OF CLAIMS AGREEMENTTransition, Separation and Release of Claims Agreement • August 7th, 2019 • Ocular Therapeutix, Inc • Pharmaceutical preparations • Massachusetts
This Transition, Separation and Release of Claims Agreement (the “Agreement”) is made as of the Agreement Effective Date (as defined below) by and between Ocular Therapeutix, Inc. (the “Company”) and Kevin Hanley (“Executive”) (together, the “Parties”).
TRANSITION, SEPARATION, AND RELEASE OF CLAIMS AGREEMENTTransition, Separation, and Release of Claims Agreement • August 27th, 2021 • Aveo Pharmaceuticals, Inc. • Pharmaceutical preparations • Massachusetts
This Transition, Separation, and Release of Claims Agreement (the “Agreement”) is made as of the Agreement Effective Date (as defined below) by and between Aveo Pharmaceuticals, Inc. (the “Company”) and Michael N. Needle, M.D. (“Executive”) (together, the “Parties”).
